Merck to face FDA adcomm in November over previously rejected potential chronic cough drug

The FDA an­nounced this morn­ing that on Nov. 17 it will hold an ad­vi­so­ry com­mit­tee meet­ing to take an­oth­er look at Mer­ck’s gefapix­ant for chron­ic cough.

While Eu­ro­pean reg­u­la­tors signed off on gefapix­ant in Ju­ly, the oral tablets ran in­to a com­plete re­sponse let­ter from FDA back in Jan­u­ary 2022, with the com­pa­ny say­ing FDA sought “ad­di­tion­al in­for­ma­tion re­lat­ed to mea­sure­ment of ef­fi­ca­cy. The CRL was not re­lat­ed to the safe­ty of gefapix­ant.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.